Notícias Chemomab Therapeutics Ltd - CMMB | Ações NASDAQ | ADVFN Brasil

Índice Bovespa

US Dollar vs BRL

As Melhores Corretoras Online

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Chemomab Therapeutics Ltd (CMMB)
Chemomab Therapeutics Ltd (CMMB) Notícias

Chemomab Therapeutics Ltd (CMMB)

1,63

0,08

(5,16%)

Fechado 26 Fevereiro 6:00PM

Atrasado por 15 minutos

1,6991

0,0691

( 4,24% )

Pré-mercado: 10:00AM

Atrasado por 15 minutos

Discussões em tempo real e ideias de negociação: Negocie com confiança com nossa poderosa plataforma.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Chemomab Completes Successful End-of-Phase 2 Meeting and Aligns with FDA on Clear and Efficient Path to Potential Regulatory Approval for Nebokitug (CM-101) in Primary Sclerosing Cholangitis

Chemomab Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Life Sciences Conference

Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit

Form POS AM - Post-Effective amendments for registration statement

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form SC 13G - Statement of Beneficial Ownership by Certain Investors

Oral Presentation at AASLD The Liver Meeting® 2024 Highlights Broad Clinical Activity of Chemomab’s CM-101 Across Multiple Biomarkers and Its Disease-Modifying Potential in Primary Sclerosing Cholangitis

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Form 424B5 - Prospectus [Rule 424(b)(5)]

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Chemomab Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Chemomab Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update

Chemomab Therapeutics Announces Late-Breaking Oral Presentation of CM-101 Phase 2 Results in Primary Sclerosing Cholangitis at AASLD The Liver Meeting® 2024

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Fóruns

Nenhuma Discussão Encontrada

Criar Nova Discussão

Chemomab Therapeutics

Vontobel Financial Produ...

Societe Generale Effekten

Amundi Index Solutions

Vontobel Financial Produ...

Vontobel Financial Produ...

AMUNDI EURO HIGH YIELD B...

IT0005615817 20250303 27

Augustum High Quality Bo...

Koninklijke Philips NV

Delayed Upgrade Clock

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições